Healthcare-related companies are expected to command investor interest in Greater China amid continued stock market euphoria seen in the sector.
“IPO performance of pre-revenue healthcare companies has been extremely well over the past 12 months,” said Max Hua, an Asia-focused partner at U.S. law firm Shearman & Sterling.
